Servier v. Poland Les Laboratoires Servier, S.A.S., Biofarma, S.A.S., Arts et Techniques du Progres S.A.S. v. Republic of Poland
Data not available
Claims arising out of the Government's withdrawal of Servier’s marketing authorisations for certain medicines, in the context of Poland’s accession to the European Union and its enactment of a series of legislative and administrative reforms to harmonise its regulation of pharmaceuticals with that of the European Union.
Secondary: C - Manufacturing
21 - Manufacture of basic pharmaceutical products and pharmaceutical preparations
PCA (Permanent Court of Arbitration)
Park, W. W.
Hanotiau, B.
Lalonde, M.
Decided in favour of investor
Interim Award on Jurisdiction dated 3 December 2010
220.00 mln EUR (300.00 mln USD)
4.00 mln EUR (5.00 mln USD)
Indirect expropriation

Fair and equitable treatment/Minimum standard of treatment, including denial of justice claims

Full protection and security, or similar

National treatment

Arbitrary, unreasonable and/or discriminatory measures
Indirect expropriation